The EVERY Company, a San Francisco-based biotech firm, has been granted a new patent (US 12/096,784) covering the scope and use of its precision fermentation-derived ovalbumin, including variants with performance enhancements from various avian species.
The patent covers the use of the novel protein in a wide range of food formulations when combined with at least one additional consumable ingredient, spanning diverse product formats such as baked goods, meat analogs, and ice cream.
This patent follows The EVERY Company's partnership announcements with major companies like Unilever , Grupo Palacios , and Grupo Nutresa as it prepares to enter the mass market with its FDA-approved ingredients: EVERY EggWhite and EVERY Protein.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.